return to news
  1. Dr Reddy’s Q1 results: Net profit declines 69% to ₹4,435 crore; revenue down over 5%; check key numbers

Market News

Dr Reddy’s Q1 results: Net profit declines 69% to ₹4,435 crore; revenue down over 5%; check key numbers

SUMMARY

Dr Reddy recorded a 69% decline in Q1 profits due to falling revenues from the global generics business. Key things investors should know about June quarter performance.

Stock list

Dr Reddy’s announced its Q1 earnings report on Wednesday, July 22, 2026. | Image: Shutterstock

Dr Reddy’s announced its Q1 earnings report on Wednesday, July 22, 2026. | Image: Shutterstock

Dr Reddy’s Q1 results: Dr Reddy's Laboratories announced its April to June quarter earnings for the financial year 2026-27 on Wednesday, July 22, where the company posted a 69% drop in net profits due to falling revenues from the global generics business.
Open FREE Demat Account within minutes!
Join now

NSE filings showed that the Dr Reddy's Laboratories’ net profit (attributable to the owners of the company) declined 69% to ₹4,435 crore in the April to June quarter results for the financial year 2026-27, compared year-on-year (YoY) with ₹14,178 crore in the same period a year ago.

The pharma company’s revenue from core operations dropped 5.5% to ₹8,070.5 crore in the first quarter results, compared to ₹8,545.2 crore in the same quarter of the previous financial year.

(This is a developing story, please stay tuned for more updates.)
Disclaimer: This article is purely for informational purposes and should not be considered investment advice from Upstox. Please consult with a financial advisor before making any investment decisions.

About The Author

Anubhav Mukherjee
Anubhav Mukherjee is a business journalist with experience at leading financial news platforms. He writes on a wide range of topics, including equity markets, corporate developments, company earnings and commodities. He holds a Post-Graduate Diploma in Business & Financial Journalism by Bloomberg from the Asian College of Journalism.

Next Story